Ohr Pharmaceutical Inc. is acquiring NeuBase Therapeutics Inc., a South Side life sciences startup that is part of the University of Pittsburgh’s LifeX portfolio of companies.
LifeX CEO Dietrich A. Stephan will be CEO of NeuBase and the company will focus on diseases caused by genetic mutations, including Huntington’s and myotonic dystrophy.
Ohr is a New York City-based pharmaceutical company that is developing therapies for ophthalmic diseases. Under the merger agreement, NeuBase stockholders will become majority holders of the combined company, which will be publicly traded on the Nasdaq under the proposed symbol of NBSE.
NeuBase’s current executive team will serve in the same capacity at the new company.
Mr. Stephan, 49, a serial entrepreneur and former chair of the Department of Human Genetics at the University of Pittsburgh School of Public Health, was named CEO of LifeX when the small business accelerator was formed in 2017. He was unavailable for comment.
Evan Facher, director of Pitt’s Innovation Institute, will replace Mr. Stephan at LifeX on an interim basis until a permanent replacement is found.
Read More
Kris B. Mamula: kmamula@post-gazette.com or 412-263-1699







Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.